EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD ...

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose ...

Heart disease is often associated with the heart and arteries, but its effects extend far beyond the cardiovascular system.

Over 537 million people globally suffer from diabetes, with 227 million in Asia Pacific. More than half may develop diabetic ...

Air pollution can severely affect eye health, leading to issues such as dry eyes, redness, itching, and more serious ...

Oculis has reported that the Phase II ACUITY trial of OCS-05, in treating individuals with acute optic neuritis, met the primary endpoint ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion. The German Institute for Quality and ...

faricimab has also been approved in Europe for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion. The German Institute for Quality and Efficiency in ...

Age-related macular degeneration (AMD) is the primary cause of vision loss in people over 65, marked by abnormal changes in the macula that lead to diminished vision and distorted perception of ...

It is important to consider the relative efficacy of the available therapies for RVO with published data. This systematic review was therefore performed to assess the efficacy and safety of ...

Seo in a media release. Age-related macular degeneration affects the macula, the part of the retina that provides central vision. (Credit: National Institutes of Health) The team, which published ...